Craft

ALX Oncology

Stock Price

$1.4

2024-10-29

Market Capitalization

$77.5 M

2024-10-29

Revenue

$1.2 M

FY, 2020

ALX Oncology Summary

Company Summary

Overview
ALX Oncology is a company that develops protein-based therapeutics intended to help in cancer treatment. Its anticancer antibodies help the immune system to eradicate cancer from the system, enabling physicians to enhance the efficacy of antibody-based therapies in clinical development.
Type
Public
Status
Active
Founded
2015
HQ
Burlingame, CA, US | view all locations
Website
http://alxoncology.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jaume Pons

    Jaume Pons, President and Chief Executive Officer, Director

    • Corey Goodman, Executive Chairman

      • Emma Abellana

        Emma Abellana, Senior Director, Finance and Controller

        • Nathan Caffo

          Nathan Caffo, Chief Business Officer

          LocationsView all

          2 locations detected

          • Burlingame, CA HQ

            United States

            866 Malcolm Rd #100

          • Dublin 2, D

            Ireland

            9, 2 Pembroke Street Upper

          ALX Oncology Financials

          Summary Financials

          Net income (Q1, 2026)
          ($17.9M)
          Cash (Q1, 2026)
          $32.3M
          EBIT (Q1, 2026)
          ($19.0M)
          Enterprise value
          $53.7M

          Footer menu